GOLPH3, a good prognostic indicator in early-stage NSCLC related to tumor angiogenesis

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 14, 2014, Pages 5793-5798

  Lu, Ming ^a   Tian, Yu ^a   Yue, Wei Ming ^a   Li, Lin ^a   Li, Shu Hai ^a   Qi, Lei ^a   Hu, Wen Si ^a   Gao, Cun ^a   Si, Li Bo ^a   Tian, Hui ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Angiogenesis; GOLPH3; Non small cell lung cancer; Prognosis

Indexed keywords

CD34 ANTIGEN; GOLPH3 PROTEIN, HUMAN; MEMBRANE PROTEIN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

AGED; BIOSYNTHESIS; DISEASE COURSE; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; MALE; METABOLISM; MICROVASCULATURE; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS;

AGED; ANTIGENS, CD34; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84905991132     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.14.5793     Document Type: Article

References (31)

1. Arriagada R, Bergman B, Dunant A, et al (2004). Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med, 350, 351-60.
2. Brognard J, Clark AS, Ni Y et al (2001). Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res, 61, 3986-97.
3. Bohm M, Wieland I, Schmidt C, et al (2001). Loss of heterozygosity on chromosome 5p13-12 predicts adverse prognosis in advanced bladder cancer independent of tumor stage and grade. J Urol , 168, 2655-58.
4. Butler JM, Kobayashi H, Rafii S (2010). Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer, 10, 138-46.
5. Crino' L, Weder W, van Meerbeeck J, et al (2001). Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, 103-15.
6. Dominik Wolf, Anna M.Wolf, Holger Rumpold, et al (2005). The expression of the regulatory T cell-specific forkhead box transcription factor Foxp3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res, 11, 8326-31.
7. Fry WA, Philips JL and Menck HR (1999). Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer, 86, 1867-76.
8. Gao W, Liu L, Lu X, et al (2011). Circulating microRNAs: possible prediction biomarkers for personalized therapy of non-small-cell lung carcinoma. Clin Lung Cancer, 12, 14-7.
9. Gorringe KL, Boussioutas A, Bowtell DD (2005). Novel regions of chromosomal amplification at 6p21, 5p13, and 12q14 in gastric cancer identified by array comparative genomic hybridization. Genes Chromosomes Cancer, 42, 247-59.
10. Guertin DA, Sabatini DM (2007). Defining the role of mTOR in cancer. Cancer cell, 12, 9-22.
11. Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell, 144, 646-74.
12. Hua X, Yu L, Pan W, et al (2012). Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer. Diagn Pathol , 7, 127.
13. Hu BS, Hu H, Zhu CY, et al (2013). Overexpression of GOLPH3 is associated with poor clinical outcome in gastric cancer. Tumour Biol, 34, 515-20.
14. Li H, Guo L, Chen SW, et al (2012). GOLPH3 overexpression correlates with tumor progression and poor prognosis in patients with clinically N0 oral tongue cancer. J Transl Med, 10, 168.
15. Mineo T C, Ambrogi V, Baldi A, et al (2004). Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol, 57, 591-97.
16. Nakashima KN, Asoh S, Ishibashi Y, et al (2005). MIDAS/ GPP34, a nuclear gene product, regulates total mitochondrial mass in response to mitochondrial dysfunction. J Cell Sci, 118, 5357-67.
17. Pignon JP, Tribodet H, Scagliotti GV, et al, on behalf of the LACE Collaborative Group (2006). Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4, 584 patients. J Clin Oncol, 24, 366s (abstract 7008).
18. Ren H, Tang X, Lee JJ, et al (2004). Expression of hepatomaderived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol, 22, 3230-37.
19. Snyder CM, Mardones GA, Ladinsky MS, et al (2006). GMx33 associates with the trans-Golgi matrix in a dynamic manner and sorts within tubules exiting the Golgi. Mol Biol Cell, 17, 511-24.
20. Smith CB, Kelley AS, Meier DE (2010). Evidence for new standard of care in non-small cell lung cancer patients. Semin Thorac Cardiovasc Surg , 22, 193-4.
21. Scott KL, Kabbarah O, Liang MC, et al (2009). GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature, 459, 1085-90.
22. Travis WD (2011). Pathology of lung cancer. Clin Chest Med, 32, 669-92.
23. Vermeulen PB, Gasparini G, Fox SB, et al (2002). Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer, 38, 1564-79.
24. Wu CC, Taylor RS, Lane DR, et al (2000). GMx33: a novel family of trans-Golgi proteins identified by proteomics. Traffic, 1, 963-75.
25. Winton T, Livingston R, Johnson D, et al (2005). Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med, 352, 2589-97.
26. Wang JH, Chen XT, Wen ZS, et al (2012). High expression of GOLPH3 in esophageal squamous cell carcinoma correlates with poor prognosis. PLoS One, 7, 45622.
27. Wang Q, Wang X, Zhang C B (2013). Lentivirus mediated GOLPH3 shRNA inhibits growth and metastasis of esophageal squamous cancer. Asian Pac J Cancer Prev, 14, 5391-96.
28. Yokoi S, Yasui K, Saito-Ohara F, et al (2002). A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol, 161, 207-16.
29. Yano T, Tanikawa S, Fujie T, et al (2002). Vascular endothelial growth factor expression and neovascularisation in nonsmall cell lung cancer. Eur J Cancer, 36, 601-9.
30. Zeng Z, Lin H, Zhao X, et al (2012). Overexpression of GOLPH3 promotes proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor. Clin Cancer Res, 18, 4059-69.
31. Zhou J, Xu T, Qin R, et al (2012). Overexpression of Golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis. J Neurooncol, 110, 195-203.